FDA Brief

Warning letters Drugs

FDA warning letter to

Lakpura LLC

High riskIssued Oct 24, 2022Posted Oct 25, 2022Center for Drug Evaluation and Research | CDER

FDA and Federal Trade Commission warned Lakpura LLC over ayurvedic products and teas with unapproved COVID-19 claims.

What happened

FDA reviewed https://lakpura.com on September 26, 2022, and the Federal Trade Commission (FTC) reviewed it on October 17, 2022. The letter says the website offered ayurvedic products and Ceylon teas with claims that they could boost immunity against, treat, or inhibit COVID-19. FDA calls the products unapproved new drugs, meaning they are sold without FDA approval, and misbranded drugs, meaning their labeling or claims violate drug law.

What FDA found

  1. FDA says the products are unapproved new drugs because they are sold with COVID-19 claims without FDA approval.

    section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. § 355(a)
  2. FDA says the products are misbranded drugs, meaning their labeling or claims violate the drug law.

    section 502 of the FD&C Act, 21 U.S.C. § 352
  3. FDA says introducing or delivering these products into interstate commerce is prohibited.

    sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d)
  4. The FTC says the company advertised that products can prevent, treat, or cure disease without competent and reliable scientific evidence.

    FTC Act, 15 U.S.C. § 41 et seq.
  5. The FTC says deceptive COVID-19 treatment, cure, prevention, or mitigation claims can bring civil penalties under the COVID-19 Consumer Protection Act.

    COVID-19 Consumer Protection Act, Section 1401, Division FF, Consolidated Appropriations Act, 2021, P.L. 116-260

What FDA wants

FDA asks the company to take immediate action to stop selling any unapproved COVID-19 products and to email a description of specific corrective steps and preventive measures within 48 hours. FTC also demands that the company immediately stop the disease claims and respond to FTC within 48 hours.

Who should pay attention

  • online retailers selling ayurvedic or herbal products
  • brands that make COVID-19 immunity or treatment claims
  • importers and distributors of Sri Lankan ayurvedic products and teas

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk